文献速递静脉血栓栓塞慢性静脉疾病

利伐沙班与艾多沙班治疗下肢深静脉血栓的有效性与安全性

The Effectiveness and Safety of Rivaroxaban and Edoxaban in the Treatment of Lower Extremity Deep Vein Thrombosis.
PubMed 文献 · Ann Vasc Surg · 2024-07-01

本研究为回顾性研究,纳入406例在我院接受利伐沙班或艾多沙班作为主要抗凝治疗的下肢深静脉血栓成年患者。艾多沙班组红细胞计数和血红蛋白较高,肺栓塞发生率显著低于利伐沙班组(P<0.001),利伐沙班组复发性血栓减少显著高于艾多沙班组,两组各部位大出血无显著差异(P>0.05)。

要点

  • 艾多沙班组肺栓塞患者少于利伐沙班组,差异有统计学意义(P<0.001)。
  • 利伐沙班组复发性血栓减少显著高于艾多沙班组。
  • 两组各部位大出血无显著差异(P>0.05)。

核心结论

  • 利伐沙班药代动力学特征包括快速吸收和相对较短半衰期,给药后迅速达血药峰浓度并在相对较短时间从体内清除。
  • 艾多沙班药代动力学特征可能包括吸收较慢、半衰期比利伐沙班长,达峰浓度速率较慢且在血循环中停留更久。
  • 这些结果强调对合并基础癌症患者需仔细考虑抗凝治疗,并在提供充分抗凝以预防血栓事件的同时重视风险管理。

研究设计与样本

  • 回顾性研究,纳入406例在我院使用直接口服抗凝药(艾多沙班和利伐沙班)治疗深静脉血栓的患者。
  • 纳入年龄18岁及以上、诊断为下肢深静脉血栓并以利伐沙班或艾多沙班作为主要抗凝治疗的成年患者。
  • 排除以其他抗凝药物(华法林和肝素)作为深静脉血栓主要治疗的患者。

主要发现

  • 两组红细胞计数和血红蛋白水平差异有统计学意义,艾多沙班组数值较高。
  • 两组肌酐清除率、白细胞计数、血小板计数、C反应蛋白和D-二聚体水平无统计学显著差异。
  • 两组肺栓塞发生率差异有统计学意义(P值<0.001),艾多沙班组肺栓塞患者少于利伐沙班组。
  • 利伐沙班组复发性血栓减少显著高于艾多沙班组。
  • 两组各部位大出血无显著差异(P>0.05)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Deep vein thrombosis (DVT) is a medical condition characterized by forming a blood clot, or thrombus, in one of the deep veins, typically in the legs. It is a type of venous thromboembolism, which refers to the formation of blood clots in the veins. It is caused by Virchow's triad (stasis, hypercoagulation, and endothelial injury). OBJECTIVE: Our main objective is to explore the effectiveness and safety of rivaroxaban and edoxaban in treating lower extremity DVT. METHODS: We conducted a retrospective study involving 406 patients subjected to DVT treatment using direct oral anticoagulants (edoxaban and rivaroxaban) at our hospital. We recruited adult patients (aged 18 years and more) diagnosed with lower extremity DVT and received treatment with either rivaroxaban or edoxaban as the primary anticoagulant therapy for DVT. We excluded patients who received treatment with other anticoagulant medications (warfarin and heparin) as the primary therapy for DVT. RESULTS: The groups showed statistically significant differences in red blood cell count and hemoglobin levels, with the edoxaban group having high values. However, the 2 groups observed no statistically significant differences in creatinine clearance, white blood cell count, platelet count, C-reactive protein, and D-dimer levels. The difference in the incidence of pulmonary embolism between the 2 groups was statistically significant (P value < 0.001). The edoxaban group had fewer pulmonary embolism patients than the rivaroxaban group. The reduction in recurrent thrombosis was significantly higher in the rivaroxaban group compared to the edoxaban group. There were no significant differences in the major bleeding at various sites across the 2 treatment groups (P > 0.05). CONCLUSIONS: Rivaroxaban's pharmacokinetic profile includes rapid absorption and a relatively short half-life. It means that once administered, rivaroxaban quickly reaches its peak concentration in the blood and is subsequently eliminated from the body within a relatively short period. Edoxaban's pharmacokinetic profile may include slower absorption and a longer half-life than rivaroxaban. It can result in a slower rate of achieving peak concentration and a more prolonged presence in the bloodstream. These results emphasize the need for careful consideration of anticoagulant therapy in patients with underlying cancer and underscore the importance of managing risks while providing adequate anticoagulation to prevent thrombotic events.

来源:Ann Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Wang L, Luo Z, Yang L, et al. The Effectiveness and Safety of Rivaroxaban and Edoxaban in the Treatment of Lower Extremity Deep Vein Thrombosis. Ann Vasc Surg. 2024. PMID: 38960092. doi:10.1016/j.avsg.2024.04.024

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。